Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24082
Full metadata record
DC FieldValueLanguage
dc.contributor.authorColes, A. J.-
dc.contributor.authorBoyko, A. N.-
dc.contributor.authorCohen, J. A.-
dc.contributor.authorDe Seze, J.-
dc.contributor.authorFox, E. J.-
dc.contributor.authorHavrdova, E.-
dc.contributor.authorHartung, H. -P.-
dc.contributor.authorInshasi, J. S.-
dc.contributor.authorMcCombe, P.-
dc.contributor.authorSelmaj, K. W.-
dc.contributor.authorVermersch, P.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorMargolin, D. H.-
dc.contributor.authorThangavelu, K.-
dc.contributor.authorRodriguez, C. E.-
dc.contributor.authorMontalban, X.-
dc.date.accessioned2017-08-04T13:45:21Z-
dc.date.available2017-08-04T13:45:21Z-
dc.date.issued2016-
dc.identifier.citationMULTIPLE SCLEROSIS JOURNAL, 22, p. 75-76 (Art N° 213)-
dc.identifier.issn1352-4585-
dc.identifier.urihttp://hdl.handle.net/1942/24082-
dc.description.sponsorshipSanofi Genzyme and Bayer HealthCare Pharmaceuticals. AJC: Consulting fees, lecture fees, and institutional grant support (Sanofi Genzyme). ANB: Consulting fees/participated in clinical trials (Bayer, Biogen, Merck Serono, Novartis, Sanofi-Aventis, Sanofi Genzyme, and Teva Pharmaceuticals). JAC: Consulting and/or speaking fees (Genentech, Novartis, Sanofi Genzyme); and compensation for serving as a journal editor, associate editor, or member of an editorial advisory board (Multiple Sclerosis Journal: Experimental, Translational and Clinical). EJF: Consulting and/or speaking fees, and grant/research support (Acorda, Bayer, Biogen, Chugai, Eli Lilly, EMD Serono, Genentech, Novartis, Opexa, Roche, Sanofi, Sanofi Genzyme, and Teva Pharmaceuticals). EH: Honoraria and grant support (Actelion, Biogen, Merck Serono, Novartis, Receptos, Roche, Sanofi Genzyme, and Teva) and is supported by Ministry of Education of Czech Republic. H-PH: Consulting and/or speaking fees (Bayer, Biogen, CSL Behring, Grifols, Merck Serono, Novartis, Roche, and Sanofi Genzyme). PM: Consulting and/or speaking fees (Biogen, Novartis, Sanofi-Aventis, and Teva Pharmaceuticals). KWS: Consulting and/or speaking fees (Biogen, Merck, Novartis, Roche, Sanofi Genzyme, and Synthon). PV: Consulting and/or speaking fees, and research support (Almirall, Bayer, Biogen, GlaxoSmithKline, Merck Serono, Novartis, Sanofi Genzyme, and Teva). BVW: Received research and travel grants, honoraria for MS-expert advice, and speakers fees (Bayer-Schering, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and Teva). DHM, KT, and CER: Employees of Sanofi Genzyme. XM: Consulting and/or speaking fees (Almirall, Bayer, Biogen, EMD, Genentech, Geneuro, Merck, Neurotec, Novartis, Roche, Sanofi, Sanofi Genzyme, and Teva Pharmaceuticals).-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.titleAlemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateSEP 14-17, 2016-
local.bibliographicCitation.conferencename32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-
local.bibliographicCitation.conferenceplaceLondon, ENGLAND-
dc.identifier.epage76-
dc.identifier.spage75-
dc.identifier.volume22-
local.format.pages2-
local.bibliographicCitation.jcatM-
dc.description.notes[Coles, A. J.] Univ Cambridge, Sch Med, Cambridge, England. [Boyko, A. N.] Pirogov Russian Natl Res Univ, Moscow, Russia. [Boyko, A. N.] Usupov Hosp, Demyelinating Dis Ctr, Moscow, Russia. [Cohen, J. A.] Cleveland Clin, Cleveland, OH 44106 USA. [De Seze, J.] Univ Strasbourg, Strasbourg, France. [Fox, E. J.] Cent Texas Neurol Consultants, Round Rock, TX USA. [Havrdova, E.] Charles Univ Prague, Med Fac 1, Prague, Czech Republic. [Hartung, H. -P.] Heinrich Heine Univ, Dusseldorf, Germany. [Inshasi, J. S.] Rashid Hosp, Dubai, U Arab Emirates. [Inshasi, J. S.] Dubai Med Coll, Dubai, U Arab Emirates. [McCombe, P.] Univ Queensland, Brisbane, Qld, Australia. [Selmaj, K. W.] Med Univ Lodz, Lodz, Poland. [Vermersch, P.] Univ Lille Nord France, Lille, France. [Van Wijmeersch, B.] Univ Hasselt, Hasselt, Belgium. [Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.] Sanofi Genzyme, Cambridge, MA USA. [Montalban, X.] MS Ctr Catalonia, Barcelona, Spain.-
local.publisher.placeLONDON-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnr213-
dc.identifier.isi000383267200122-
item.fulltextWith Fulltext-
item.contributorColes, A. J.-
item.contributorBoyko, A. N.-
item.contributorCohen, J. A.-
item.contributorDe Seze, J.-
item.contributorFox, E. J.-
item.contributorHavrdova, E.-
item.contributorHartung, H. -P.-
item.contributorInshasi, J. S.-
item.contributorMcCombe, P.-
item.contributorSelmaj, K. W.-
item.contributorVermersch, P.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorMargolin, D. H.-
item.contributorThangavelu, K.-
item.contributorRodriguez, C. E.-
item.contributorMontalban, X.-
item.fullcitationColes, A. J.; Boyko, A. N.; Cohen, J. A.; De Seze, J.; Fox, E. J.; Havrdova, E.; Hartung, H. -P.; Inshasi, J. S.; McCombe, P.; Selmaj, K. W.; Vermersch, P.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E. & Montalban, X. (2016) Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).. In: MULTIPLE SCLEROSIS JOURNAL, 22, p. 75-76 (Art N° 213).-
item.accessRightsOpen Access-
crisitem.journal.issn1352-4585-
crisitem.journal.eissn1477-0970-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Alemtuzumab provides durable improvements in clinical outcomes in treatment.pdfPeer-reviewed author version447.95 kBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

10
checked on Oct 14, 2024

Page view(s)

116
checked on Sep 7, 2022

Download(s)

4
checked on Sep 7, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.